Coyote attacks child, 8, in Frisco
The Brief
An 8-year-old in Frisco is recovering after being attacked by a coyote on Monday while walking with her mother.
The child sustained non-life-threatening injuries before her mother chased the animal away.
Three coyotes have been removed from the neighborhood for testing; it's currently unknown if the attacking coyote was diseased.
FRISCO, Texas - An 8-year-old from Frisco is recovering from injuries after a coyote attack on Monday, officials say.
The Frisco Police Department's Wednesday release says the attack happened while the child was walking with her mother in a Frisco neighborhood.
What we know
The attack happened around 4:05 p.m. in the Lexington Park community near Lacy Lane and Tall Timbers Trail, the PD said in their release.
They say the child was walking ahead of her mother when she was attacked by the coyote.
The 8-year-old suffered non-life-threatening injuries, the city said, including scratches and a bite. The mother was able to chase the animal away.
Following the attack, Frisco Animal Services and representatives from the United States Department of Agriculture's Texas Wildlife Services Program were able to find and remove three coyotes from the neighborhood, Frisco PD said. The coyotes have been sent for testing.
What we don't know
The release does not say whether the coyote is suspected to have been carrying a disease.
What you can do
The PD's release includes recommendations on how to handle an interaction with an aggressive coyote:
While walking or jogging, consider carrying something that makes a loud noise to scare off an animal, such as an airhorn or whistle.
If you walk small animals, ensure they are on a leash.
Do not allow domesticated animals to roam freely outdoors.
Do not approach or feed wildlife and keep trash in a secure container.
Anyone who observes what appears to be an aggressive animal should contact the Frisco Police Department at (972) 292-6010 or call 911.
The Source
Information in this article comes from the City of Frisco.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Small but 'life-changing' policy helps Parkinson's patients who need emergency care at Guelph's hospital
When people go to the emergency department, they're not allowed to take their own medications while they wait, which Theresa Daly says can be a huge problem for people with Parkinson's. A long-time nurse and social worker who actively works in Parkinson's disease support groups, Daly says she's thrilled the hospital in Guelph, Ont., has recently made a tweak to a long-standing practice to make it easier for Parkinson's patients to take their medications on time. "It's life-changing," Daly said. "Life-giving and life-saving and certainly quality of life saving." Hospitals have a policy that any medication given while a person is in the hospital must be through the pharmacy or a physicians order. Hospitals will monitor every patient's medication to avoid mixing, doubling up, choking or even overdosing. But emergency departments can be very busy and this can lead to people not getting medications on time. One of the more common medications for Parkinson's is Levodopa, used to control some of the physical deterioration symptoms. Daly says when a dose is missed, it can lead to people not feeling "normal" again for days, weeks or even months afterwards. The new policy at Guelph General Hospital says, an emergency department nurse is able to give permission to those with Parkinson's to take the medication they brought from home. Daly volunteers with the southwestern Ontario branch of Parkinson Canada and her brother also has the disease. She says she's very familiar with the toll the conditions take on both a sufferer and their loved ones. "To see them move into suffering because they haven't had their medication on time affects two people. The person with Parkinson's and the one who loves them. So it's a big deal," Daly said. Parkinson's disease is a neurological and degenerative condition. It has no cure and can get worse over time. The most commonly known issues from PD include slowness of movement, rigidity, tremors and instability. There are other symptoms associated with the condition including insomnia, anxiety, depression, bladder issues, faintness, leg swelling, heavy sweating, double vision and a multitude of other challenges. Ian Smith has Parkinson's and in the past few months, he's had to go to Guelph General Hospital three times. "[Parkinson's patients] all have different problems, some more than others ... and generally, hospitals don't like you bringing your own pills in," he said. While Smith doesn't always feel drastic effects if he misses a pill, he's familiar with how demanding the medication schedule can be. He takes three pills a day with specific food and timing restrictions. "My little Parkinson pill isn't high on the priority list because nobody has told them that it should be," Smith said. By allowing Parkinson's patients to monitor their medication, he said it's less stress for both them and, he assumes, the medical professionals. Andrea de Jong is the director of the emergency department Guelph General Hospital hospital. She said it's become a successful best practice to give emergency room nurses the power and knowledge to administer medications without having to get an order from a physician. She said there are still restrictions on who is able to administer Parkinson's medication that's brought in from home, but nurses are very familiar with these guidelines. "This ideally helps them go back home quicker and overall have a better experience here," she said. Daly said that Guelph General Hospital was very quick to approve this directive with their emergency department teams and medical advisory committee and said it's in line with much of the work Parkinson Canada aims to do within hospitals. A patient's knowledge of their own rights and their ability to advocate is a separate hurdle, she said. "There's a double prong education piece to this... people with Parkinson's have to know that it was okay, and emerge has to know that they have Parkinson's and that it's important they get their pills on time," Daly said. Parkinson Canada spokesperson Emma Gostovic told CBC News that the organization wasn't aware of any other hospitals in the country with a similar directive for Parkinson's patients and their medications. Most hospitals are still aware this is a concern and are conscious of medication timing, she said. Gostovic called Guelph General Hospital's model one they'd like to "explore and share with others throughout the clinical community."
Yahoo
a day ago
- Yahoo
Sanofi announces new data from two clinical studies on Sarclisa
New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously via an on-body injector in relapsed or refractory multiple myeloma support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa's efficacy and safety profile. The results were presented at the American Society of Clinical Oncology Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous infusion. The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection. The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections' enFuse hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa. The enFuse device uses a 30 gauge, hidden, and retractable needle that is smaller compared to some of the commonly used large-volume SC injection needles, which may support patient comfort. The safety and efficacy of Sarclisa SC administered with the OBI or manual administration are investigational and have not been approved for use by any regulatory authority. IRAKLIA is a global, randomized, open-label, pivotal phase 3 non-inferiority study comparing Sarclisa SC administered via an OBI and Sarclisa IV, both in combination with pomalidomide and dexamethasone in adult patients with R/R MM who have received at least one prior line of treatment. At the data cut-off of November 6, 2024, and a median follow-up of 12 months, the study demonstrated: Primary endpoints: Objective response rate with Sarclisa SC-Pd was 71.1% compared to 70.5% with Sarclisa IV-Pd, establishing non-inferiority. Observed Sarclisa mean concentration before dosing at steady state with Sarclisa SC-Pd was 499 ug/mL compared to 341 ug/mL with Sarclisa IV-Pd, establishing non-inferiority. Secondary endpoints Very good partial response or better rates were consistent between Sarclisa SC-Pd and Sarclisa IV-Pd at 46.4% and 45.9%, respectively. Observed Sarclisa mean C trough at 4 weeks with Sarclisa SC-Pd was 421 ug/mL compared to 302 ug/mL with Sarclisa IV-Pd. Systemic infusion reactions were significantly lower with Sarclisa SC-Pd, occurring in only 1.5% of patients compared to 25% of those treated with Sarclisa IV-Pd. Of note, nearly all IRs occurring were grade 1 or 2 and resolved within one day. No patients in the Sarclisa SC-Pd arm discontinued treatment due to a systemic IR. Most Sarclisa SC-Pd-treated patients reported being satisfied or very satisfied with their injection compared to 53.4% in the Sarclisa IV-Pd arm, demonstrating the positive impact of this innovative method of administration on the patient experience. 99.9% of Sarclisa SC OBI injections were successfully delivered with no significant safety concerns related to the OBI. Progression-free survival rates at 12 months were also similar, reaching 66.1% for patients treated with Sarclisa SC-Pd compared to 65.1% of patients treated with Sarclisa IV-Pd. The overall safety profile of Sarclisa SC-Pd observed in this study was consistent with the established safety profile of Sarclisa IV-Pd, but with a notably lower rate of systemic IRs. No new safety concerns were observed, except for low-grade local injection site reactions associated with SC administration that occurred with a low incidence. Nearly all ISRs were grade 1, except for one episode of grade 2. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on SNY: Disclaimer & DisclosureReport an Issue Sanofi price target raised to EUR 110 from EUR 108 at Guggenheim Sanofi price target lowered to EUR 118 from EUR 120 at Berenberg Oppenheimer bullish on Nurix as Sanofi opt-in, competitor data derisk STAT6 Sanofi price target lowered to EUR 108 from EUR 121 at Guggenheim Morning Movers: Trump to bump steel tariffs, pharma companies announce deals Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal
On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for treatment-resistant depression (TRD), generally defined as a failure on two or more antidepressants. Alto paid Chase Therapeutics an upfront payment of $1.75 million. Chase Therapeutics will be eligible for up to $71.5 million in milestone payments, $41 million of the potential future milestone payments are tied to the product candidates' commercial success. Alto expects its current cash balance to support planned operations into 2028 through five clinical trial readouts across its pipeline most advanced program, ALTO-207 (formerly known as CTC-501), is a fixed-dose combination of pramipexole, a dopamine D3-preferring D3/D2 agonist, approved for Parkinson's disease with demonstrated antidepressant effect, and ondansetron, an antiemetic, selective 5-HT3 receptor antagonist. As a fixed-dose combination, ALTO-207 enables rapid titration and higher dosing by mitigating the dose-limiting adverse events typically experienced with pramipexole. Phase 2a trial of CTC-501 Chase Therapeutics completed a Phase 2a trial evaluating CTC-501 in 32 patients with depression. The primary endpoint was achieved in the study. Patients randomized to receive CTC-501 reached a mean dose of 4.1mg per day, with 67% achieving the highest allowable dose of 5mg/day. CTC-501 was generally well tolerated in the maintenance period of the study. CTC-501 demonstrated statistically significant and clinically meaningful improvements from baseline compared to placebo on depression symptoms as measured by the Montgomery Åsberg Depression Rating Scale or MADRS. CTC-501 also demonstrated significantly greater improvement on the Clinician Global Impression Scale of Severity (CGI-S) compared to placebo. Alto expects to initiate a Phase 2b trial, designed to be a potentially pivotal study, with ALTO-207 in patients with TRD by mid-2026 and report topline data in 2027. Phase 2a Trial For CTC-413 ALTO-208 (or CTC-413) is a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist. ALTO-208 is being developed for patients with Parkinson's disease (PD). Chase Therapeutics completed a blinded Phase 2a trial evaluating CTC-413 in 13 patients with PD. The mean tolerated dose of CTC-413 significantly exceeded pramipexole. Six subjects (67%) tolerated CTC-413 at the maximum dose of 9.0mg/day, and all but one remained on that dose throughout the final three-month treatment period. CTC-413 demonstrated favorable safety and tolerability with no unexpected, serious or persistent issues. William Blair reiterated an Outperform rating on Alto Neuroscience, viewing the acquisition of ALTO-207 as an 'intriguing asset.' The firm noted the impressive efficacy of pramipexole in the PAX-D study but also highlighted the possibility of functional unblinding in that study, which may have contributed to the perceived efficacy. Price Action: ANRO stock is trading higher by 2.31% to $2.66 at last check Tuesday Read Next:Photo by fizkes via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
